Page last updated: 2024-10-24

verapamil and Autosomal Dominant Juvenile Parkinson Disease

verapamil has been researched along with Autosomal Dominant Juvenile Parkinson Disease in 1 studies

Verapamil: A calcium channel blocker that is a class IV anti-arrhythmia agent.
verapamil : A racemate comprising equimolar amounts of dexverapamil and (S)-verapamil. An L-type calcium channel blocker of the phenylalkylamine class, it is used (particularly as the hydrochloride salt) in the treatment of hypertension, angina pectoris and cardiac arrhythmia, and as a preventive medication for migraine.
2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile : A tertiary amino compound that is 3,4-dimethoxyphenylethylamine in which the hydrogens attached to the nitrogen are replaced by a methyl group and a 4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl group.

Research Excerpts

ExcerptRelevanceReference
"(1) Parkinsonian syndromes have occasionally been attributed to diltiazem, a calcium channel blocker, sometimes with a positive rechallenge."1.32Parkinsonian syndrome and calcium channel blockers. ( , 2003)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Other Studies

1 other study available for verapamil and Autosomal Dominant Juvenile Parkinson Disease

ArticleYear
Parkinsonian syndrome and calcium channel blockers.
    Prescrire international, 2003, Volume: 12, Issue:64

    Topics: Amlodipine; Calcium Channel Blockers; Diltiazem; Humans; Parkinsonian Disorders; Verapamil

2003